Verona Pharma plc Sponsored ADR Forecast, price target & analysts
Verona Pharma plc Sponsored ADR Target price 2025 - Analyst rating & recommendation
Verona Pharma plc Sponsored ADR Classifications & Recommendation:
Verona Pharma plc Sponsored ADR Price Target
| Target Price | $74.44 |
| Price | $67.12 |
| Potential |
10.91%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2026 .
The average Verona Pharma plc Sponsored ADR target price is $74.44.
This is
10.91%
register free of charge
$93.00
38.56%
register free of charge
$52.00
22.53%
register free of charge
|
|
| A rating was issued by 9 analysts: 9 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2026 of
10.91%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 37.76 |
| 100.00% |
9 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2024 . The average Verona Pharma plc Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2024 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2024. The average Verona Pharma plc Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.69 | -1.90 |
| 33.65% | 175.36% | |
| P/E | negative | |
| EV/Sales | 134.69 |
2 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Verona Pharma plc Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Verona Pharma plc Sponsored ADR...
Current Verona Pharma plc Sponsored ADR Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 12 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 21 2025 |
| Roth MKM | Locked ➜ Locked | Locked | Jan 10 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Jan 08 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Jan 08 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Nov 05 2024 |
| Wells Fargo | Locked ➜ Locked | Locked | Nov 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 21 2025 |
|
Locked
Roth MKM: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Nov 05 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
